|
1
|
Trenta P, Calabro F, Cerbone L and
Sternberg CN: Chemotherapy for Muscle-invasive bladder cancer. Curr
Treat Options Oncol. 17:62016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Massari F, Santoni M, Ciccarese C,
Brunelli M, Conti A, Santini D, Montironi R, Cascinu S and Tortora
G: Emerging concepts on drug resistance in bladder cancer:
Implications for future strategies. Crit Rev Oncol Hematol.
1:81–90. 2015. View Article : Google Scholar
|
|
3
|
Grossman HB, Natale RB, Tangen CM,
Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF,
Wood DJ, Raghavan D and Crawford ED: Neoadjuvant chemotherapy plus
cystectomy compared with cystectomy alone for locally advanced
bladder cancer. N Engl J Med. 9:859–866. 2003. View Article : Google Scholar
|
|
4
|
International Collaboration of Trialists;
Medical Research Council Advanced Bladder Cancer Working Party (now
the National Cancer Research Institute Bladder Cancer Clinical
Studies Group); European Organisation for Research and Treatment of
Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer
Study Group; National Cancer Institute of Canada Clinical Trials
Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club
Urologico Espanol de Tratamiento Oncologico Group, . Griffiths G,
Hall R, et al: International phase III trial assessing neoadjuvant
cisplatin, methotrexate, and vinblastine chemotherapy for
muscle-invasive bladder cancer: Long-term results of the BA06 30894
trial. J Clin Oncol. 16:2171–2177. 2011.
|
|
5
|
Advanced Bladder Cancer Meta-analysis
Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer:
A systematic review and meta-analysis. Lancet. 361:1927–1934. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yafi FA, North S and Kassouf W: First- and
second-line therapy for metastatic urothelial carcinoma of the
bladder. Curr Oncol. 1:e25–e34. 2011.
|
|
7
|
von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cummings BS, Lasker JM and Lash LH:
Expression of glutathione-dependent enzymes and cytochrome P450s in
freshly isolated and primary cultures of proximal tubular cells
from human kidney. J Pharmacol Exp Ther. 293:677–685.
2000.PubMed/NCBI
|
|
10
|
Galluzzi L, Vitale I, Michels J, Brenner
C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems
biology of cisplatin resistance: Past, present and future. Cell
Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Buttigliero C, Tucci M, Vignani F,
Scagliotti GV and Di Maio M: Molecular biomarkers to predict
response to neoadjuvant chemotherapy for bladder cancer. Cancer
Treat Rev. 54:1–9. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Quinn JE, Kennedy RD, Mullan PB, Gilmore
PM, Carty M, Johnston PG and Harkin DP: BRCA1 functions as a
differential modulator of chemotherapy-induced apoptosis. Cancer
Res. 63:6221–6228. 2003.PubMed/NCBI
|
|
14
|
Hoffmann AC, Wild P, Leicht C, Bertz S,
Danenberg KD, Danenberg PV, Stöhr R, Stöckle M, Lehmann J, Schuler
M and Hartmann A: MDR1 and ERCC1 expression predict outcome of
patients with locally advanced bladder cancer receiving adjuvant
chemotherapy. Neoplasia. 8:628–636. 2010. View Article : Google Scholar
|
|
15
|
De P, Carlson J, Leyland-Jones B and Dey
N: Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A
(CIP2A): An oncoprotein with many hands. Oncotarget. 5:4581–4602.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao F, Xu T, Wang X, Zhong S, Chen S,
Zhang M, Zhang X, Shen Y, Wang X, Xu C and Shen Z: CIP2A mediates
fibronectin-induced bladder cancer cell proliferation by
stabilizing β-catenin. J Exp Clin Cancer Res. 36:702017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang CY, Chao TT, Chang FY, Chen YL, Tsai
YT, Lin HI, Huang YC, Shiau CW, Yu CJ and Chen KF: CIP2A mediates
erlotinib-induced apoptosis in non-small cell lung cancer cells
without EGFR mutation. Lung Cancer. 85:152–160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu P, Yao J, He J, Zhao L, Wang X, Li Z
and Qian J: CIP2A down regulation enhances the sensitivity of
pancreatic cancer cells to gemcitabine. Oncotarget. 7:14831–14840.
2016.PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 4:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Rajeswaran A, Trojan A, Burnand B and
Giannelli M: Efficacy and side effects of cisplatin- and
carboplatin-based doublet chemotherapeutic regimens versus
non-platinum-based doublet chemotherapeutic regimens as first line
treatment of metastatic non-small cell lung carcinoma: A systematic
review of randomized controlled trials. Lung Cancer. 59:1–11. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
David KA, Milowsky MI, Ritchey J, Carroll
PR and Nanus DM: Low incidence of perioperative chemotherapy for
stage III bladder cancer 1998 to 2003: A report from the National
Cancer Data Base. J Urol. 178:451–454. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xue Y, Wu G, Wang X, Zou X, Zhang G, Xiao
R, Yuan Y, Long D, Yang J, Wu Y, et al: CIP2A is a predictor of
survival and a novel therapeutic target in bladder urothelial cell
carcinoma. Med Oncol. 30:4062013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang LP, Savoly D, Sidi AA, Adelson ME,
Mordechai E and Trama JP: CIP2A protein expression in high-grade,
high-stage bladder cancer. Cancer Med. 1:76–81. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pang X, Fu X, Chen S, Zhu X, Qi H, Li Y,
Li F and Tan W: Overexpression of CIP2A promotes bladder cancer
progression by regulating EMT. Clin Transl Oncol. 18:289–295. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Basu A and Tu H: Activation of ERK during
DNA damage-induced apoptosis involves protein kinase Cdelta.
Biochem Biophys Res Commun. 334:1068–1073. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jones EV, Dickman MJ and Whitmarsh AJ:
Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase.
Biochem J. 405:617–623. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hayakawa J, Mittal S, Wang Y, Korkmaz KS,
Adamson E, English C, Ohmichi M, McClelland M and Mercola D:
Identification of promoters bound by c-Jun/ATF2 during rapid
large-scale gene activation following genotoxic stress. Mol Cell.
16:521–535. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lucas CM, Milani M, Butterworth M, Carmell
N, Scott LJ, Clark RE, Cohen GM and Varadarajan S: High CIP2A
levels correlate with an antiapoptotic phenotype that can be
overcome by targeting BCL-XL in chronic myeloid leukemia. Leukemia.
30:1273–1281. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Janghorban M, Farrell AS, Allen-Petersen
BL, Pelz C, Daniel CJ, Oddo J, Langer EM, Christensen DJ and Sears
RC: Targeting c-MYC by antagonizing PP2A inhibitors in breast
cancer. Proc Natl Acad Sci USA. 111:9157–9162. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chao TT, Wang CY, Chen YL, Lai CC, Chang
FY, Tsai YT, Chao CH, Shiau CW, Huang YC, Yu CJ and Chen KF:
Afatinib induces apoptosis in NSCLC without EGFR mutation through
Elk-1-mediated suppression of CIP2A. Oncotarget. 6:2164–2179. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
McLaughlin M, Barker HE, Khan AA, Pedersen
M, Dillon M, Mansfield DC, Patel R, Kyula JN, Bhide SA, Newbold KL,
et al: HSP90 inhibition sensitizes head and neck cancer to
platin-based chemoradiotherapy by modulation of the DNA damage
response resulting in chromosomal fragmentation. BMC Cancer.
17:862017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kritsch D, Hoffmann F, Steinbach D, Jansen
L, Photini Mary S, Gajda M, Mosig AS, Sonnemann J, Peters S,
Melnikova M, et al: Tribbles 2 mediates cisplatin sensitivity and
DNA damage response in epithelial ovarian cancer. Int J Cancer.
141:1600–1614. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Smith J, Tho LM, Xu N and Gillespie DA:
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and
cancer. Adv Cancer Res. 108:73–112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma CX, Janetka JW and Piwnica-Worms H:
Death by releasing the breaks: CHK1 inhibitors as cancer
therapeutics. Trends Mol Med. 17:88–96. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Basu B, Yap TA, Molife LR and de Bono JS:
Targeting the DNA damage response in oncology: Past, present and
future perspectives. Curr Opin Oncol. 24:316–324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Khanna A, Kauko O, Böckelman C, Laine A,
Schreck I, Partanen JI, Szwajda A, Bormann S, Bilgen T, Helenius M,
et al: Chk1 targeting reactivates PP2A tumor suppressor activity in
cancer cells. Cancer Res. 73:6757–6769. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Myant K, Qiao X, Halonen T, Come C, Laine
A, Janghorban M, Partanen JI, Cassidy J, Ogg EL, Cammareri P, et
al: Serine 62-phosphorylated MYC associates with nuclear lamins and
its regulation by CIP2A is essential for regenerative
proliferation. Cell Rep. 12:1019–1031. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liao Y and Hung MC: Physiological
regulation of Akt activity and stability. Am J Transl Res. 2:19–42.
2010.PubMed/NCBI
|
|
40
|
Bozulic L, Surucu B, Hynx D and Hemmings
BA: PKBalpha/Akt1 acts downstream of DNA-PK in the DNA
double-strand break response and promotes survival. Mol Cell.
30:203–213. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hayakawa J, Ohmichi M, Kurachi H, Kanda Y,
Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T and Murata Y:
Inhibition of BAD phosphorylation either at serine 112 via
extracellular signal-regulated protein kinase cascade or at serine
136 via Akt cascade sensitizes human ovarian cancer cells to
cisplatin. Cancer Res. 60:5988–5994. 2000.PubMed/NCBI
|
|
42
|
Tseng LM, Liu CY, Chang KC, Chu PY, Shiau
CW and Chen KF: CIP2A is a target of bortezomib in human triple
negative breast cancer cells. Breast Cancer Res. 14:R682012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen KF, Liu CY, Lin YC, Yu HC, Liu TH,
Hou DR, Chen PJ and Cheng AL: CIP2A mediates effects of bortezomib
on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
Oncogene. 29:6257–6266. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wiegering A, Pfann C, Uthe FW, Otto C,
Rycak L, Mäder U, Gasser M, Waaga-Gasser AM, Eilers M and Germer
CT: CIP2A influences survival in colon cancer and is critical for
maintaining Myc expression. PLoS One. 10:e752922013. View Article : Google Scholar
|
